About
TRex Bio, Inc.
TRex Bio, Inc. develops immunoregulatory biologics for autoimmune and inflammatory diseases in United States and Internationally.
The company operates the Deep Biology Platform, a drug discovery and design platform that integrates tissue-level insights into human biology and treg function to identify and characterize therapeutic targets, using computational mapping, which uses in silico tools and a human tissue bank and atlas of human treg gene expression to identify pathways in tissue immune regulation; the Treg Atlas, which recreates tissue states in tregs and reprograms blood-derived Tregs to recreate human tissue-specific pathways in vitro for target validation; and the Phenotypic Assay Cascade, a suite of high-throughput functional fingerprinting assays that test targets across donors and inflammatory contexts.
The company develops TRB-061 an investigational tumor necrosis factor receptor 2 (TNFR2) agonist and fragment crystallizable-fusion (Fc-fusion) protein designed to selectiv
TRex Bio, Inc. Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Change from offer price to today
Live Market Snapshot
Real-time price; headline % change is vs first trade (listing price)
USD · NASDAQ:NASDAQ:TRXB
Valuation & Multiples
Key valuation ratios and metrics
Financial Health
Balance sheet strength and liquidity
Financial Highlights
Historical financial performance
Historical Data
Market history and supplemental quote data
| Date | Open | High | Low | Close | Adj. Close | Change | Volume |
|---|---|---|---|---|---|---|---|
| 2026-10-30 | $13.66 | $13.86 | $13.10 | $13.74 | $13.74 | +0.08 | 39,200 |
| 2026-10-29 | $14.15 | $14.31 | $13.42 | $13.52 | $13.52 | -0.63 | 33,600 |
| 2026-10-28 | $13.94 | $14.49 | $13.36 | $14.43 | $14.43 | +0.49 | 79,600 |
| 2026-10-27 | $14.00 | $14.14 | $13.69 | $13.79 | $13.79 | -0.21 | 42,900 |
| 2026-10-26 | $13.80 | $14.64 | $13.56 | $13.87 | $13.87 | +0.07 | 55,000 |
| 2026-10-23 | $15.39 | $15.50 | $13.51 | $13.81 | $13.81 | -1.58 | 81,200 |
| 2026-10-22 | $15.45 | $16.21 | $15.00 | $15.50 | $15.50 | +0.05 | 67,500 |
| 2026-10-21 | $14.59 | $16.56 | $14.10 | $15.24 | $15.24 | +0.65 | 88,600 |
| 2026-10-20 | $14.80 | $15.01 | $14.22 | $14.44 | $14.44 | -0.36 | 64,200 |
| 2026-10-19 | $14.28 | $15.40 | $13.94 | $14.80 | $14.80 | +0.52 | 113,500 |
| 2026-10-16 | $14.17 | $14.40 | $13.55 | $14.01 | $14.01 | -0.16 | 81,900 |
| 2026-10-15 | $13.50 | $14.35 | $13.50 | $14.16 | $14.16 | +0.66 | 88,700 |
| 2026-10-14 | $13.41 | $14.05 | $13.21 | $13.50 | $13.50 | +0.09 | 398,800 |
| 2026-10-13 | $13.95 | $14.08 | $13.47 | $13.60 | $13.60 | -0.35 | 121,900 |
| 2026-10-12 | $14.19 | $14.36 | $13.75 | $14.03 | $14.03 | -0.16 | 189,000 |
| 2026-10-09 | $13.50 | $15.50 | $13.50 | $14.00 | $14.00 | +0.50 | 1,257,000 |
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| SCHEDULE 13G | Oct 16, 2026 | Filing |
| SCHEDULE 13D | Oct 16, 2026 | Filing |
| SCHEDULE 13D | Oct 16, 2026 | Filing |
| SCHEDULE 13G | Oct 15, 2026 | Filing |
| 8-K | Oct 13, 2026 | Current Report |
| S-8 | Oct 9, 2026 | Securities to be offered to employees in employee benefit plans |
| 424B4 | Oct 9, 2026 | Prospectus |
| EFFECT | Oct 8, 2026 | Notice of Effectiveness |
| CERT | Oct 8, 2026 | Certification by an exchange approving securities for listing |
| 8-A12B | Oct 6, 2026 | Registration of securities |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
M. Johnston Erwin, Jr.
Chief Executive Officer and Chair
Laura Berner
Chief Operating Officer
Brandon Hants
Chief Financial Officer
Ariella Kelman
Chief Medical Officer
Ali Zarrin
Chief Scientific Officer
Carol G. Gallagher
Director and Lead Independent Director
Alexandra Cantley
Director
Travis Coy
Director
Julie Gilmore
Director
Peter Hirth
Director
